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Abstract: Many studies investigated the use of antiepileptic drugs (AEDs) in several neurological diseases other than  
epilepsy. These neurological disorders, usually, involve neuronal excitability through the modulating of ion channels,  
receptors and intracellular signaling pathways, and are the targets of the AEDs. This article provides a review of the  
clinical efficacy of both conventional and newer AEDs in hyperkinetic movement disorders. Some of these indications  
for AEDs have been established, while others are under investigation. The modulation of GABAergic transmission may  
explain the neuronal hyper-excitability that underlies some forms of hyperkinetic movement disorders. So, AEDs able to 
increase GABAergic neurotransmission may play a role in hyperkinetic movement disorders treatment. Therefore, AEDs 
could represent a useful therapeutic option in the management of hyperkinetic movement disorders where the available 
treatments are ineffective. 
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INTRODUCTION 
  Antiepileptic drugs (AEDs), extensively used in the 
treatment of epilepsy, are usually classified into conventional 
and newer ones (see Table 1). 
  The first group includes among others: bezodiazepines, 
carbamazepine, phenobarbital phenytoin and valproate, 
while the second one comprises: felbamate, gabapentin, 
lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topi-
ramate, vigabatrin and zonisamide [1-4]. Most of these drugs 
act via more than one mechanism of action, so AEDs may be 
divided into three principal groups: 1) blockers of voltage-
dependent sodium and calcium channels, so they reduce 
high-frequency repetitive firing in neurons: carbamazepine, 
oxcarbazepine, gabapentin, lamotrigine, phenobarbital, 
phenytoin, topiramate, and valproate; 2) enhancers of 
GABA-mediated events (via the interaction with specific 
binding sites on the GABA-A receptor complex, the inhibi-
tion of GABA metabolism or the reduction of its neuronal 
uptake): benzodiazepine, gabapentin, phenobarbital, tiaga-
bine, topiramate, vigabatrin, valproate; 3) blockers of the T-
type calcium channels: ethosuximide and zonisamide [1-4]. 
An additional category of AEDs, comprising drugs which 
directly reduce the excitation mediated by ionotropic   
glutamate NMDA (i.e felbamate) and AMPA/kainite (i.e 
phenobarbital, topiramate) receptors, may be added [1, 3-6]. 
However, the exact mechanisms of action of the newer 
AEDs are not still fully clarified.  
  Initial studies show the new agents to be equally effica-
cious but overall better tolerated than traditional agents. In  
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addition, most of the new agents have a more favorable 
pharmacokinetic profile with limited hepatic metabolism, 
fewer drug interactions and adverse effects, i.e. cognitive 
impairment, hepatotoxicity and skin rash [2, 4, 7]. 
Table 1.  Classification of Antiepileptic Drugs  
Conventional AEDs  Newer AEDs 
Acetazolamide Felbamate 
Carbamazepine   Gabapentin 
Clobazam Lamotrigine   
Clonazepam Levetiracetam 
Diazepam Oxcarbazepine 
Ethosuccimide Pregabalin 
Phenytoin Tiagabine 
Phenobarbital Topiramate   
Lorazepam Vigabatrin   
Piracetam Zonisamide   
Primidone    
Valproate  
 
  However, AEDs are extensively used to treat a wide 
range of disorders other than epilepsy, including both neuro-
logical and psychiatric conditions [4, 8]. The use of AEDs in 
other conditions is currently being explored [9]. 
  The main pharmacodynamic mechanisms responsible for 
the clinical efficacy of AEDs in non-epileptic disorders in-
clude the modulation of both gamma-aminobutyric acidergic 360    Current Neuropharmacology, 2010, Vol. 8, No. 4  Siniscalchi et al. 
(GABAergic) or glutamatergic neurotransmission and the 
modulation of voltage-gated ion channels or intracellular 
signalling pathways [9, 10]. Current knowledge indicates 
that several AEDs have more than one mechanism of action, 
contributing to their therapeutic efficacy [10]. However, in-
direct mechanisms may be also involved, such as modulation 
of other neurotransmitters, including the monoamine. Con-
clusive evidences of the effects of AEDs on other neuro-
transmitter systems has not been published. One study de-
scribes the changes in monoamine and metabolites plasma 
levels during the treatment with lamotrigine, carbamazepine 
and phenytoin [11]. Valproate is one of the most thoroughly 
studied AEDs and its effects on other neurotransitters have 
been reviewed by Löscher [12]. Disordered function of 
GABAergic neurons in the basal ganglia may be responsible 
of several involuntary movements, the hallmarks of hyperki-
netic disorders.  
  Hyperkinetic movement disorders include tremor, parox-
ysmal dyskinesias (dystonia and chorea), myoclonus, restless 
legs syndrome, hemifacial spasms and other disorders [13-
16]. Pathophysiologically, these disorders are characterized 
by a reduced basal ganglia outpout resulting in a dis-
inhibition of the thalamo-cortical systems, releasing cortical 
motor areas to allow movements that would normally be 
suppressed. Furthermore, the specific manifestations of the 
hyperkinetic disease may be determined by presence or ab-
sence of other abnormalities, such as in the patterning or the 
level of synchronization of basal ganglia output [17]. Evi-
dences supported that the efficacy of AEDs in hyperkinetic 
movement disorders is still inadequate for many of these 
disorders, even if newer AEDs, which are more tolerability, 
are under investigations. Therefore, it is important to im-
prove the clinical trials in larger numbers of patients with 
homogeneity of diagnosis, to establish the efficacy of the 
AEDs.  
  The purpose of the present review is to relate the mecha-
nisms of action of AEDs to pathophysiological mechanisms 
and clinical efficacy in hyperkinetic movement disorders 
(Table 2). 
Table 2.  The Main Indication for Conventional and Newer AEDs in Hyperkinetic Movement Disorders. X= Effective Drug; 0=Not 
Effective Drug; ET= Essential Tremor; RLS= Restless Legs Syndrome; HFS= Hemifacial Spasms 
Conventional Antiepiletic Drugs  ET  Dystonia  Choreoathetosis/Ballism  Myoclonus  RLS  HFS 
Primidone X 
(19, 23) 
        
Clonazepam X 
(21) 
X 
(19, 67-69) 
 X 
(82) 
 X 
(106) 
Pnenytoin   X 
(19, 67, 68) 
      
Acid valproic      X 
(73-76) 
X 
(82, 85) 
X 
(4, 96, 101) 
 
Carbamazepine   X 
(19, 67, 68) 
X 
(19, 75, 77) 
 X 
(4, 96) 
X 
(105) 
Newer Antiepiletic drugs 
Gabapentin X/0 
(8, 25) 
 X 
(79) 
 X 
(4, 96) 
X 
(111) 
Pregabalin X/0 
(28, 42) 
       X 
(110) 
Felbamate           X 
(107) 
Oxcarbazepine     X 
(48) 
 X 
(100) 
 
Topiramate X 
(29-31, 38) 
X 
(19, 67, 68) 
X 
(80, 81, 96) 
X 
(90) 
X 
(103) 
X 
(112) 
Levetiracetam X/0 
(37-39, 41) 
X 
(19, 67, 68) 
X 
(50, 78) 
X 
(87, 88) 
 X 
(108, 109) 
Zonisamide X 
(27, 33) 
       X 
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DRUGS TREATMENT OF HYPERKINETIC MOVE-
MENT DISORDERS 
1. Essential Tremor 
  Essential tremor (ET) is a progressive neurological disor- 
der characterized by a synchronous activation of antagonistic  
muscles [18] and it is defined as a rythmical, involuntary   
oscillatory movement induced by alternative contraction of  
agonist and antagonist muscles [8, 19]. ET may be caused by  
a deficiency in the 1-subunit  of  GABA-A receptor, as   
documented in a knockout model of mice [59]. This mecha- 
nism elucidates that a dysfunction in GABAergic system in  
the major motor pathway represents a potential target for   
pharmacotherapy, and benzodiazepines, which are GABA-A  
receptor agonists, may be efficacious in ET treatment [20,  
21]. This animal model overlaps with ET in humans and   
shows a loss of inhibitory neurotransmission by cerebellar  
Purkînje cells, without the presence of Purkînje cells degen- 
eration [19]. Moreover, it has been reported that diazepam  
had no effect on ET, whereas dizocilpine is able to reduce  
tremor, reflecting that functionality and pharmacological   
sensitivity may be altered in genetic models, and impairment  
of contributes to essential tremor [20, 21]. Based on their  
mechanisms of action, AEDs that enhance GABAergic neu- 
rotransmission could be effective in the treatment of ET.   
Drugs with this potential include conventional (primidone,   
clonazepam) and newer AEDs (tiagabine, gabapentin,   
pregabalin, topiramate, levetiracetam and zonisamide). 
  Primidone is the most effective drug used in the treat-
ment of ET, even if it may be related with the development 
of toxic side-effects (e.g. nausea, vomiting, sedation, confu-
sion, and ataxia) [22, 23]. The anti-tremor effects of primi-
done have been confirmed by several open trials and pla-
cebo-controlled studies and it is recommended (level A) by 
the American Academy of Neurology [23]. The efficacy of 
primidone in the management of ET is mostly attributed to 
the parent compound rather than to its metabolites phen-
ylethyl-malonamide or phenobarbital. In some patients, 
primidone might be more efficacious than propranolol, and a 
combination of the two drugs might be more efficacious than 
either drug alone [22]. In addition to propanolol and primi-
done, the benzodiazepine drugs (such as clonazepam) could 
play a role in ET treatment [24]. The newer AEDs able to 
enhance the GABAergic neurotransmission, e.g. gabapentin, 
pregabalin, topiramate and possibly levetiracetam, may play 
a role in the treatment of neurological disorders such as ET 
[10]. In a clinical study Gironell et al. [25] showed that 
gabapentin had the same efficacy of propranolol and was 
better than placebo. In contrast, in another previous study, 
with a small number of patients, no statistical differences 
was documented between gabapentin and placebo [26]. Ze-
siewicz  et al. 2007 [27] documented the efficacy of pre-
gabalin in the management of ET, but recently in a clinical 
study this improvement has not been found, even if the ad-
verse events (the most common were drowsiness and dizzi-
ness) were similar in frequency in both clinical studies [28]. 
The effect of topiramate in essential tremor has been re-
ported in several trials [29-31]. This effect could be ex-
plained by the proposed mechanism of action of topiramate, 
such as the modulation of GABA-A receptor [10]. In an old 
man with ET unresponsive to primidone treatment, the com-
bined therapy of topiramate and declorazepam induced a 
rapid improvement of symptoms supporting a synergic effect 
of both drugs [32] 
  The positive effect of zonisamide on ET has been well 
reported [27, 33] also in patients with associated head tremor 
[34]. Although modulation of voltage-gated ion channels 
represents the main mechanism of action of zonisamide, it is 
also able to enhances the GABA release, to downregulate the 
number of GABA reuptake transporter proteins and to 
upregulate the glutamate transporter EAAC-1 [8, 35]. The 
effect of levetiracetam in both ET and cerebellar tremor 
seems to be promising and needs to be investigated in larger 
patient groups [36-38]. The primary site of action of 
levetiracetam seems to be the synaptic vesicle protein 2C 
(SV2A) possibly inhibiting the neurotransmitters release. 
Levetiracetam is also able to enhance the chloride currents in 
GABA-A receptor [39, 40]. It has been suggested that exocy-
tosis of the excitatory neurotransmitter glutamate is inhibited 
by levetiracetam, and this could explain its clinical efficacy 
in ET, since the enhancement of GABAergic neurotransmis-
sion and the decrease in glutamatergic neurotransmission 
seem to be advantageous to reduce the ET [20]. However, 
another one study in fifteen patients, failed to demonstrate 
the efficacy of levetiracetam [41]. Recently tiagabine, a cen-
trally acting GABA reuptake inhibitor, has been reported to 
exacerbate ET [42] while an open label trial in 5 ET patients 
revealed both the lack of clinical efficacy and the higher   
adverse events [43]. 
2. Paroxysmal Dyskinesias (PKD)  
  Paroxysmal dyskinesias are a heterogenous group of hy-
perkinetic movement disorders recurring in an episodic fash-
ion [44, 45]. If sudden movements trigger the attacks, the 
term paroxysmal kinesigenic dyskinesia (PKD) is used [46]. 
The typical clinical picture in such cases is of brief attacks of 
chorea/dystonia (seconds to minutes) affecting a limb that 
are precipitated by sudden movements [47]. In most patients, 
one limb or side of the body is more frequently affected than 
the other, and the attacks are typically unilateral, even if 
generalized attacks are occasionally reported. This condition 
is usually responsive to AEDs [19, 45].  
  In fact, Chillag and Deroos in a retrospective study re-
ported a complete resolution of idiopathic paroxysmal kine-
sigenic dyskinesia in four patients treated with lower-doses 
of oxcarbazepine monotherapy [48]. 
  The pathophysiology of PKD is unclear at the time of 
this review. However, neuronal ion channelopathies have 
been documented in several paroxysmal movement disorders 
such as episodic ataxia type 1 (KCNA1) and type 2 
(CANCA1) [12, 36, 49, 50] and in paroxysmal neurological 
disorders without associated movement disorders including 
familial hemiplegic migraine [51-54] and some forms of 
familial epilepsy [48, 55, 56].  
  Thus considering the paroxysmal character of the attacks, 
the presence of prodromic aura-like symptoms, the short 
time of the attacks and their response to AEDs [57, 58], it is 
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disorders at subcortical levels. In agreement with this hy-
pothesis, several reports documented the presence of people 
with different age-related expression affected by both PKD 
and epilepsy [33, 59]. On the other hand, the occurrence of 
dystonia in 70-80% of PKD episodes might indicate a patho-
physiological process similar to primitive dystonia, where 
deficits in cortical, brainstem and spinal inhibitory circuits, 
due to disordered basal ganglia modulation of cortical motor 
output, have been detected. Evidence to support the role of 
the basal ganglia in the pathophysiology of PKD is the ob-
servation of secondary PKD in patients with focal basal gan-
glia lesions [60]. Recently, Fourcad et al. [61] in a study in 
19 patients, supported the hypothesis that channel dysfunc-
tion and basal ganglia lesions may be together involved in 
the pathophysiology of PKD. Moreover, Huang and Hwang 
[62] described that a few epilepsy and paroxysmal move-
ment disorders are "channelopathies", indicating that they 
may share some commons pathophysiological mechanisms 
and a possible "overlap".  
2.1. Dystonia 
  Dystonia is defined as a neurological disorder dominated 
by sustained muscle contractions, which frequently cause 
twisting, repetitive, and patterned movements or abnormal 
postures [63]. Dystonic movements can be slow, manifested 
by prolonged dystonic spasms resulting in abnormal pos-
tures, or can be rapid and jerk-like movements [19, 64]. 
Dystonia might also present as a rhythmical movement, most 
noticeable when the patient attempts to correct the underly-
ing abnormal dystonic posture [19, 64]. This dystonic tremor 
can be abolished if the patient is asked to relax and allow the 
body part to move in the direction of the dystonic pull (null 
position) [19, 64].  
  The adult-onset idiopathic dystonias, the most common 
dystonic disorders seen in neurological practice, are usually 
focal and remain focal or segmental [17, 19, 64]. Examples 
include cranial dystonia (blepharospasm or oromandibular or 
lingual dystonia), cervical dystonia (spasmodic torticollis), 
laryngeal dystonia (spasmodic dysphonia), and dystonic 
writer’s cramp [22, 65]. Pharmacological treatment is largely 
empiric, rather than scientific. Attacks of kinesigenic parox-
ysmal dystonia can be controlled with anticonvulsants (car-
bamazepine, phenytoin, levetiracetam, topiramate and 
gabapentin) [19, 66-68]. The non- kinesigenic form of par-
oxysmal dystonia are less responsive to pharmacological 
treatment, even if clonazepam might be used [69]. 
2.2. Chorea 
  Chorea consists of irregular, purposeless, abrupt, rapid, 
brief, jerky, unsustained movements that flow randomly 
from one part of the body to another [19, 65, 70]. 
  The term “choreoathetosis” describes the combination of 
chorea and athetosis, a slow form of chorea manifested by 
writhing movements predominantly involving distal extremi-
ties [19, 65, 70] 
  Ballism, a severe form of chorea, comprises wide ampli-
tude, flinging movements, usually involves the proximal 
limbs and most often affects only one side of the body 
(hemiballism) [19, 65, 70, 71]. 
  Typically a lesion in the contralateral subthalamic nu-
cleus is the cause of ballism, however, pathology in other 
subcortical areas could be also involved. Rarely, ballism can 
occur bilaterally (biballism or paraballism) [19, 65, 71]. 
Many patients with ballism have also distal choreic move-
ments and, as recovery occurs, hemiballism often transform 
into hemichorea and hemidystonia [19, 65]. Chorea is de-
fined as primary when it is idiopathic or genetic in origin or 
secondary when it is related to other causes (i.e. such as vas-
cular, metabolic and immunologic diseases, infections and 
drugs) [70-72]. The pathophysiological processes for pri-
mary neurodegenerative chorea, such as Huntington's dis-
ease, clearly involve both excitotoxicity and the inhibition of 
histone acetylation, accompanied by the loss of GABAergic 
medium-sized spiny neurons in the striatum [71-73]. 
  The AEDs can be efficacious in choreiform movements. 
In particular, valproate potentiates the GABA activity and 
modulates the potassium channels and could be also able to 
have direct membrane-stabilizing effects [74-76]. Recently, 
Zadori and co-workers [73] documented in an experimental 
model of Huntington's disease that chronic intraperitoneal 
administration of valproate ameliorates the survival and the 
motor performance. Therefore valproate’s action may be 
mediated by both GABAergic and antiexcitotoxic effects, 
but could be also related to the inhibition of histone deacety-
lase. Carbamazepine can also reduce the choreiform move-
ments in some patients through the stabilization of inacti-
vated state of voltage-gated sodium channels [74, 75, 77]. 
The newer AEDs, may represent an alternative in the treat-
ment of paroxysmal kinesiogenic choreoathetosis; in fact, 
gabapentin and levetiracetam have been reported to be useful 
in the management of patient with hemichorea/hemiballism 
[78, 79], while topiramate is reported to improve both vascu-
lar hemichorea/hemiballism [80, 81] and vascular general-
ized chorea [55]. Moreover, recently Vlas and co-workers 
[50] described the efficacy of levetiracetam (start dose of 
2.5mg⁄kg⁄day, titrated to a final dose of 10mg⁄kg⁄day) to re-
duce choreoathetosis in two patients with dyskinetic cerebral 
palsy, without the development of side effects. 
3. Myoclonus 
  Myoclonus is defined as sudden jerks typically lasting 10 
to 50 milliseconds, with the duration of movements rarely 
longer than 100 milliseconds [14]. Myoclonus is usually a 
positive phenomenon, causing synchronized muscle contrac-
tions in single or multiple muscle groups. Myoclonus jerks 
can be irregular, rhythmic, or even oscillatory, due to a dys-
function in cortical, brainstem, or spinal motor system. Neu-
rodegenerative syndromes, encephalitis, and toxic-metabolic 
disorders responsible for cortical injuries may cause myo-
clonus with or without seizures. Myoclonus occurs as an 
ictal phenomenon in many epilepsy syndromes including 
idiopathic (e.g. juvenile myoclonic epilepsy of JME), symp-
tomatic (e.g. myoclonic epilepsy or infancy) and progressive 
disorders (e.g. Lafora body disease). 
  Myoclonus may be induced by hyperexcitability of many 
neurons at several levels of the motor system as a result of 
neuronal injury or degenerative disorder. The dysfunction of 
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ability that underlies some forms of myoclonus. GABA me-
diates the majority of fast inhibitory synaptic transmission in 
the CNS; glycine is the inhibitory transmitter for some neu-
rons in the brainstem and spinal cord [82]. The postsynaptic 
GABA and glycine receptors are pentameric arrangements of 
subunits around a central pore that conducts chloride when 
opened by transmitter binding, thereby inhibiting the post-
synaptic cells. Bicuculline and picrotoxin, GABA-A receptor 
antagonists, can induce myoclonus [24, 82]. Animal models 
of myoclonus have been generated by producing alterations 
of postsynaptic GABA-A and glycine receptors [83]. Dys-
function of GABAergic system in the pre-motoneuronal cir-
cuitry may be responsible for the generation of spinal myo-
clonus. A previous study performed in a patient with rhyth-
mic segmental myoclonus documented the presence of  hy-
peractivity  in the dorsal horn inhibitory interneurons [84]. 
However, drugs that increase GABAergic transmission, like 
clonazepam and valproate are the first-line treatments for 
myoclonus [82, 85]. Clonazepam is a direct agonist of the 
GABA-A receptor [82], while valproic acid is an indirect 
agonist and increases the brain GABA levels without interac-
tion with the receptor [82]. In a clinical study the myoclonic 
hyperkinesias in Huntington’s disease patients showed a 
dose-depended improvement with valproate [85]. Moreover, 
on GABA-A receptor, levetiracetam is able to blocks the 
effects of the negative allosteric modulators (i.e. zinc) [86]. 
Previous studies indicate that levetiracetam is effective in the 
treatment of cortical and spinal myoclonus [87, 88]. Al-
though a disorder of spinal inhibitory interneurons is the 
favored pathology in most cases of spinal myoclonus, his-
tological evidence exists in which motoneurons are prime 
candidate [84]. The hyperexcitability of the motoneuron 
could be due to overactivity of postsynaptic excitatory neu-
rotransmission or to changes in the distribution of voltage-
gated channels in the membrane [89]. In agreement, we re-
ported a case of a patient with segmental myoclonus in an 
amputation stump that ameliorated markedly after the treat-
ment with topiramate, probably due to the reduction of mo-
toneuronal hyperactivity through a decrease of glutamate 
function at postsynaptic sites or to inhibition of sodium and 
calcium currents [90]. However, this effect has not docu-
mented with gabapentin treatment. In fact, has been well 
reported that gabapentin at the dose from 600 mg to 1, 800 
mg may increase the risk of development of de novo myo-
clonus or worsening of myoclonus in patients with preexis-
tent myoclonus in about 2 weeks of treatment [91]. 
4. Restless Legs Syndrome 
  Restless legs syndrome (RLS) is a a sensorimotor disor-
der common in people over 65 years old and characterized 
by an irresistible urge to move the legs, accompanied by 
uncomfortable and unpleasant sensations that diminish with 
motor activity and worsen at rest [92]. These symptoms 
worsen in the evening and at night, leading to difficulty in 
sleeping and therefore can induce insomnia and depression. 
This syndrome can be a primary disorder or a secondary one, 
associated with for example iron-deficiency, uremia or poly-
neuropathies [92, 93].  
  The specific pathophysiology of idiopathic RLS is not 
well known but recent studies have raised the hypothesis of 
diencephalospinal pathway dysfunction. This pathway in-
cludes spinal, subcortical and cortical structures [94, 95]. 
  Some patients (typically with painful symptoms) may be 
responsive to carbamazepine, gabapentin, valproic acid and 
benzodiazepines [36, 96]. Carbamazepine demonstrated its 
efficacy in relieving paresthesia in two placebo-controlled 
studies [4], but it is not recommended for occurrence of toxic 
side effects and drug interactions [97-99]. 
  However, the efficacy of oxcarbazepine has recently been 
documented in three patients with RLS [100]. Gabapentin 
(dosage: 200 mg up to 2,000 mg, mean: 800-1,855 mg) 
could be efficacious for the treatment of RLS, but current 
evidence is limited to randomized double-blind controlled 
studies and two randomized controlled studies [96].   
Valproate is likely efficacious for the treatment of RLS,   
even if the special monitoring is recommended for side   
effects, like hepatotoxicity [101].  
  Benzodiazepines, especially clonazepam, could be useful 
for intermittent RLS symptoms and because of their hypnotic 
effects they may be particularly useful to treat sleep onset 
insomnia caused by RLS [96, 102]. In this syndrome, topi-
ramate is considered to be investigational [103]. However, at 
the moment, the use of AEDs remain the second-line option 
in the treatment of RLS. 
5. Hemifacial Spasms 
  Hemifacial spasm (HFS) is a potentially disabling clini-
cal disorder characterized by chronic twitching or spasm of 
on side of the facial muscles innervated by seventh cranial 
nerve [56]. The  pathophysiological mechanisms for the 
genesis and maintenance of HFS have not yet been defined, 
however it results from vascular compression of the facial 
nerve at the root entry zone [56, 104]. The recent use of 
ADEs could be related to the reduction of the hyperexcitabil-
ity of the nucleus of the seventh nerve. These effects may be 
mediated by 1) a block of voltage-sensitive sodium and T-
type calcium channels, 2) a reduction of excitatory glutama-
tergic transmission and 3) an enhancement of GABAergic 
neurotransmission [3, 10]. 
  There are only isolated reports of pain improvement in 
HFS patients using ADEs such as carbamazepine [105], 
clonazepam [106], felbamate [107], levetiracetam [108, 
109], pregabalin [110], gabapentin [66, 111] and topiramate 
[112]. Moreover, we recently reported a patient with   
idiopathic HFS responsive to zonisamide-treatment [113].  
CONCLUSION AND DIRECTIONS FOR FUTURE 
RESEARCH 
  The primary indication for AEDs remains certainly epi-
lepsy, even if other neurological conditions may be treated 
with these drugs when the typical treatments are ineffective. 
Several pathophysiological mechanisms inducing a neuronal 
excitability seems to be involved in an imbalance of both 
GABAergic and glutamatergic neurotransmissions and there-
fore could be similar in epilepsy and hyperkinetic movement 
disorders. The main targets for the action of the AEDs in-
clude enhancement of GABAergic inhibition, decreased glu-
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and calcium channels, and effects on intracellular signalling 
pathways. All of these mechanisms are of importance in con-
trolling neuronal excitability in different ways. Future re-
search on intracellular mechanisms might become decisive 
for a better understanting of the similarities between epilepsy 
and these disorders. Clinical observation, however, suggests 
that compared with conventional AEDs, the newer AEDs are 
more tolerated and have less pharmacodynamic interactions 
[7].  
  In the treatment of hyperkinetic movement disorders   
there is the potential to use pharmacological agents with   
GABA-potentiating properties, and GABAergic hypofunc- 
tion in the basal ganglia is cited as an important mechanism  
underlying the pathophysiology of several  hyperkinetic  
movement disorders. AEDs that seem to enhance GABAergic  
neurotransmission can be seen to have a role in these  
neurological disorders. AEDs with effects on decreasing   
glutamatergic  neurotransmission  on  and/or  voltage  sodium  
or calcium channels may be advantageous in several hyper- 
kinetic movement disorders, like PKD,  spinal  myoclonus  
and HFS. Research supporting the efficacy of AEDs in the  
management of hyperkinetic movement disorders is still   
inadequate and there are only isolated reports regarding the  
role of AEDs in HFS patients. So, more prospective clinical  
trials are necessary to confirm the efficacy of both conven- 
tional and newer AEDs in hyperkinetic movement disorders  
and determine better the proportion of responders in a larger  
group of patients. 
  Current studies reported the clinical impact of pharmaco-
genetics on the pharmacological treatment of epilepsy. The 
genes may influence the outcome of drug treatment in indi-
viduals epileptic patients, in term of clinical efficacy and 
themselves may contribute to the development of side effects 
during treatment, that is the principal cause for dropped out 
of patients in clinical studies [114]. In fact, has been well 
reported that Asian patients HLA-B 1502 positive are at a 
higher risk for Stevens-Johnson syndrome during the treat-
ment with carbamazepine [12]. 
  Although many factors may contribute to variability of 
clinical outcome in individual patients, unpredictability   
differences in efficacy and adverse drug reactions, such as  
optimal doses of AEDs in patients with hyperkinetic move- 
ment disorders may be related to genetic variations.  
  So, in the future, a better understanding of the AEDs 
mechanisms of actions in different hyperkinetic movement 
disorders should be provided by increased knowledge of the 
underlying molecular deficits in these disorders.  
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